Epoxide hydrolase: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
Michal Harel (talk | contribs)
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 2: Line 2:
== Function ==
== Function ==


'''Epoxide hydrolase''' (EH) converts epoxides to trans-dihydrodiols which are excreted from the body.  Thus, EH acts as a detoxification agent.  Epoxides are formed from degradation of aromatic compounds<ref>PMID:18585390</ref>.<br />  '''Bifunctional EH 2''' or '''soluble EH''' (SEH) is a bifunctional enzyme with the C-terminal domain having EH activity and the N-terminal domain having lipid phosphatase activity.<br />  '''Limonene-1,2-epoxide hydrolase''' catalyzes the conversion of limonene-1,2-epoxide to limonene-1,2-diol<ref>PMID:12773375</ref> .
'''Epoxide hydrolase''' (EH) converts epoxides to trans-dihydrodiols which are excreted from the body.  Thus, EH acts as a detoxification agent.  Epoxides are formed from degradation of aromatic compounds<ref>PMID:18585390</ref>.<br />  '''Bifunctional EH 2''' or '''soluble EH''' (SEH) is a bifunctional enzyme with the C-terminal domain having EH activity and the N-terminal domain having lipid phosphatase activity.<br />  '''Limonene-1,2-epoxide hydrolase''' catalyzes the conversion of limonene-1,2-epoxide to limonene-1,2-diol<ref>PMID:12773375</ref> .  For details see [[limonene-1,2-epoxide hydrolase]].


== Disease ==
== Disease ==
Line 14: Line 14:


<scene name='70/708145/Cv/7'>Inhibitor binding site</scene> (PDB code [[5alf]]).<ref>PMID:25931264</ref>
<scene name='70/708145/Cv/7'>Inhibitor binding site</scene> (PDB code [[5alf]]).<ref>PMID:25931264</ref>
</StructureSection>


== 3D Structures of epoxide hydrolase==
== 3D Structures of epoxide hydrolase==
[[Epoxide hydrolase 3D structures]]


Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}}
</StructureSection>
{{#tree:id=OrganizedByTopic|openlevels=0|
 
*Epoxide hydrolase
 
**[[2e3j]] – EH B – ''Mycobacterium tuberculosis''<br />
**[[1qo7]], [[3g02]] – AnEH (mutant) – ''Aspergillus niger''<br />
**[[2cjp]] – pEH I – potato<br />
**[[3cxu]], [[4ufn]], [[4ufo]], [[4ufp]], [[4uhb]], [[4y9s]] – pEH (mutant) <br />
**[[4i19]], [[4qa9]], [[4f4z]] – EH – ''Streptomyces carzinostaticus''<br />
 
*Soluble epoxide hydrolase
 
**[[1s8o]], [[3i1y]], [[3i28]], [[3koo]], [[5ahx]], [[5fp0]] – hSEH – human<br />
**[[1cqz]] – mSEH – mouse<br />
**[[4nzz]] – BmSEH – ''Bacillus megaterium''<br />
**[[4inz]] – BmSEH (mutant) <br />
**[[1ehy]] – SEH – ''Agrobacterium tumefaciens''<br />
 
*Epoxide hydrolase complex with inhibitor
 
**[[3g0i]] – AnEH + valpromide<br />
**[[3rga]] – SlEH + oxazolidinone inhibitor – ''Streptomyces lasaliensis''<br />
**[[4rzm]] – SlEH + lasalocid A<br />
 
*Soluble epoxide hydrolase complex with inhibitor
 
**[[1vj5]], [[1zd2]], [[1zd3]], [[1zd4]], [[1zd5]], [[3wk4]], [[4c4x]], [[4c4y]], [[4c4z]], [[5ai5]], [[5akz]], [[5ali]] – hSEH + urea derivative inhibitor<br />
**[[1cr6]], [[1ek1]], [[1ek2]] – mSEH + urea derivative inhibitor<br />
**[[3otq]], [[3wk7]], [[4y2j]], [[4y2s]], [[4y2v]], [[5ak4]], [[5akh]], [[5aki]], [[5alk]], [[5alq]], [[5alv]], [[5aly]] – hSEH + pyrazole inhibitor<br />
**[[5akj]], [[5alf]], [[5als]] – hSEH + imidazole inhibitor<br />
**[[5akk]], [[5ald]], [[5aln]], [[5alo]], [[5alw]], [[5am4]] – hSEH + indolone inhibitor<br />
**[[5akx]], [[5aky]] – hSEH + indazole inhibitor<br />
**[[3wk5]], [[3wk6]], [[3wk8]], [[3wk9]], [[3wkc]], [[5ai8]], [[5aic]], [[5akg]], [[5alg]] – hSEH + thiazole derivative inhibitor<br />
**[[3ans]], [[3ant]] – hSEH + synthetic inhibitor<br />
**[[3pdc]], [[5ale]]  – hSEH catalytic domain + benzoxazole inhibitor<br />
**[[4jnc]], [[5alx]] – hSEH catalytic domain + carboxamide inhibitor<br />
**[[4x6x]], [[4x6y]]  – hSEH catalytic domain + cyclopropane inhibitor<br />
**[[4hai]], [[3wka]], [[4ocz]], [[4od0]], [[5ake]], [[5alh]], [[5am1]] – hSEH + piperidine derivative inhibitor<br />
**[[4y2p]], [[4y2q]], [[5ai4]], [[5ak5]], [[5ak6]], [[5alt]], [[5am5]] – hSEH + pyridine derivative inhibitor<br />
**[[4y2r]] – hSEH + piperazine derivative inhibitor<br />
**[[5akl]], [[5alm]], [[5am0]] – hSEH + pyrrolidine derivative inhibitor<br />
**[[4y2t]], [[5aib]] – hSEH + benzyloxy derivative inhibitor<br />
**[[3wkb]]  – hSEH + quinoxaline derivative inhibitor<br />
**[[4y2u]], [[5ai6]], [[5alj]], [[5alr]], [[5am2]] – hSEH + quinoline derivative inhibitor<br />
**[[4y2x]], [[5alu]], [[5alz]] – hSEH + adamantanyl derivative inhibitor<br />
**[[4y2y]] – hSEH + etylmethyamine derivative inhibitor<br />
**[[3wkd]], [[5alp]] – hSEH + morpholine derivative inhibitor<br />
**[[3wke]], [[5am3]] – hSEH + carbamoyl derivative inhibitor<br />
**[[4j03]] – hSEH + fulvestrant<br />
**[[5ai0]] – hSEH + phenyl oxadiazolamine inhibitor<br />
**[[5ai9]] – hSEH + phenol derivative inhibitor<br />
**[[5aia]] – hSEH + benzoate derivative inhibitor<br />
**[[5ak3]] – hSEH + indan-amine derivative inhibitor<br />
**[[5all]] – hSEH + cyclohexyl methanol inhibitor<br />
**[[4o08]] – BmSEH + phenoxy acetamide inhibitor<br />
 
*Soluble epoxide hydrolase complex with product
 
**[[4io0]] – BmSEH + naphthyloxy propane diol<br />
 
*Limonene-1,2-epoxide hydrolase
 
**[[1nww]] – ReEH – ''Rhodococcus erythropolis''<br />
**[[4r9k]], [[4r9l]], [[4xbx]], [[4xdw]], [[5cf1]], [[5cf2]], [[5jpp]] – ReEH (mutant)<br />
**[[1nu3]] – ReEH + valpromide <br />
**[[4xbt]], [[4xdv]], [[5clk]], [[5jpu]] – ReEH (mutant) + cyclohexanediol<br />
**[[4xby]], [[5ck6]] – ReEH (mutant) + cyclopentene oxide<br />
**[[5aif]], [[5aih]], [[5aii]] – mlEH – metagenomic library<br />
**[[5aig]] – mlEH + valpromide <br />


}}
== References ==
== References ==
<references/>
<references/>
[[Category:Topic Page]]
[[Category:Topic Page]]

Latest revision as of 13:10, 31 August 2020

Function

Epoxide hydrolase (EH) converts epoxides to trans-dihydrodiols which are excreted from the body. Thus, EH acts as a detoxification agent. Epoxides are formed from degradation of aromatic compounds[1].
Bifunctional EH 2 or soluble EH (SEH) is a bifunctional enzyme with the C-terminal domain having EH activity and the N-terminal domain having lipid phosphatase activity.
Limonene-1,2-epoxide hydrolase catalyzes the conversion of limonene-1,2-epoxide to limonene-1,2-diol[2] . For details see limonene-1,2-epoxide hydrolase.

Disease

Inhibitors of Mycobacterium tuberculosis EH such as urea derivatives, are used as anti-tuberculosis drugs. The valpromide inhibitor of EH is used as anti-epileptic drug. Soluble EH plays a role in several diseases including cardiovascular ones and is a drug target for their therapy [3].

Relevance

Structural highlights

.

(PDB code 5alf).[4]

3D Structures of epoxide hydrolase

Epoxide hydrolase 3D structures


Human soluble epoxide hydrolase complex with imidazole derivative inhibitor (PDB code 5alf)

Drag the structure with the mouse to rotate

ReferencesReferences

  1. Biswal BK, Morisseau C, Garen G, Cherney MM, Garen C, Niu C, Hammock BD, James MN. The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor. J Mol Biol. 2008 Sep 12;381(4):897-912. Epub 2008 Jun 17. PMID:18585390 doi:10.1016/j.jmb.2008.06.030
  2. Arand M, Hallberg BM, Zou J, Bergfors T, Oesch F, van der Werf MJ, de Bont JA, Jones TA, Mowbray SL. Structure of Rhodococcus erythropolis limonene-1,2-epoxide hydrolase reveals a novel active site. EMBO J. 2003 Jun 2;22(11):2583-92. PMID:12773375 doi:http://dx.doi.org/10.1093/emboj/cdg275
  3. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009 Oct;8(10):794-805. doi: 10.1038/nrd2875. PMID:19794443 doi:http://dx.doi.org/10.1038/nrd2875
  4. Oster L, Tapani S, Xue Y, Kack H. Successful generation of structural information for fragment-based drug discovery. Drug Discov Today. 2015 Apr 28. pii: S1359-6446(15)00154-3. doi:, 10.1016/j.drudis.2015.04.005. PMID:25931264 doi:http://dx.doi.org/10.1016/j.drudis.2015.04.005

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Alexander Berchansky, Joel L. Sussman